BENZOPYRAN ISOMERS

Abstract: The (3S, 4R)-isomer of compounds of formula (1) option­ ally in admixture with up to 45% of the mixture by weight of the corresponding (3R, 4S)-isomer: wherein: one of R₁ and R₂ is hydrogen and the other is selected from the class of alkylcarbonyl, alkoxycarbonyl, alkylcar­ bonyloxy, alkylhydroxymethyl, nitro, cyano, chloro, trif­ luoromethyl, alkylsulphinyl, alkylsulphonyl, alkoxysulphinyl, alkoxysulphonyl, alkylcarbonylamino, alkoxycarbonylamino or aminosulphinyl, aminosulphonyl or aminocarbonyl, the amino moiety being optionally substituted by one or two alkyl groups, or alkylsulphinylamino, alkylsulphonylamino, alk­ oxysulphinylamino or alkoxysulphonylamino or ethylenyl terminally substituted by alkylcarbonyl, nitro or cyano, or -C(alkyl)NOH or -C(alkyl) NNH₂, the alkyl groups or alkyl moieties of alkyl-containing groups having from 1 to 6 carbon atoms; one of R₃ and R₄ is hydrogen or alkyl having from 1 to 4 carbon atoms and the other is alkyl having from 1 to 4 carbon atoms, or R₃ and R₄ together are C₂₋₅ polymethylene; R₅ is hydrogen, alkyl having from 1 to 3 carbon atoms or acyl having from 1 to 8 carbon atoms; and n is 1 or 2, having pharmacological activity, in particular anti-­ hypertensive activity, a process for the preparation of such isomers, their pharmaceutical use and pharmaceutical com­ positions containing them.

Description: ACTIVE COMPOUNDS The present invention relates to one isomeric form of chemical compounds having pharmacological activity, to a process for the preparation of such isomers, and to their pharmaceutical use, and to pharmaceutical compositions containing them. European patent publication 9912 dislcoses the compound, 6-cyano-3,4-dihydro-2,2-dimethyl-trans 4-pyrrolidino-2H-benzo[b]pyran-3-ol, which has blood pressure lowering activity. It also dislcoses that the (+)-isomer has greater blood pressure lowering activity than the (-)- isomer. It has now been discovered that, in relation to a class of 3,4-dihydrobenzopyran-3-ols and the corresponding ethers and esters, characterised by being substituted in the 4-position by a pyrrolidon-l-yl or piperidon-l-yl radical trans to the 3-hydroxy, -ether or -ester group, one isomer, namely the (3S,4R) -isomer, has greater blood pressure lowering activity than the other isomer, namely the (3R,4S)-isome. Accordingly, the present invention provides the (3S,4R)-isomer of a compound of formula (I) optionally in admixture with up to 45% of the mixture by weight of the corresponding (3R,4S)-isomer: EMI2.1 wherein: one of R1 and R2 is hydrogen and the other is selected from the class of alkylcarbonyl, alkoxycarbonyl, alkylcarbonyloxy, alkylhydroxymethyl, nitro, cyano, chloro, trifluoromethylr alkylsulphinyl, alkylsulphonyl, alkoxysulphinyl, alkoxysulphonyl, alkylcarbonylamino, alkoxycarbonylamino or aminssulphinyl, aminosulphonyl or aminocarbonyl, the amino moiety being optionally substituted by one or two alkyl groups, or alkylsulphinylamino, alkylsulphonylamino, alkoxysulphinylamino or alkoxysulphonylamino or ethylenyl terminally substituted by alkylcarbonyl, nitro or cyano, or -C(alkyIYNOH or -C(alkyl)NNH2, the alkyl groups or alkyl moieties of alkyl-containing groups having from 1 to 6 carbon atoms; one of R3 and R4 is hydrogen or alkyl having from 1 to 4 carbon atoms and the other is alkyl having from 1 to 4 carbon atoms, or R3 and R4 together are C25 polymethylene; R5 is hydrogen, alkyl having from 1 to 3 carbon atoms or acyl having from 1 to 8 carbon atoms; and n is 1 or 2. The (more active) (3S,4R)-isomer of a compound of formula (I) is of formula (it): EMI3.1 wherein the variables are as defined in formula (I). The (more active) (3S,4R)-isomers of compounds of formula (I) have the same configuration as that enantiomer of a compound of formula (III) which has a negative optical rotation: EMI3.2 the '9 and pyrrolidon-l-yl groups in formula (III) being mutually trans. The compound of formula (III) is trans-6-cyano-3,4-dihydro-2,2-dimethyl-4-(2-oXo-1- pyrrolidinyl)-benzo[b]pyran-3-ol. The other isomer of a compound of formula (I), i.e. the (3R,4S)-isomer, has the same configuration as the other enantiomer of the compound of formula (III), that is the enantiomer which has a positive optical rotation. A group of isomers of formula (11) is that wherein each isomer has a negative optical rotation, that is, it is the (-)-isomer. The other isomer has a positive optical rotation, that is, it is the (+)-isomer. The ahsolute configuration of each isomer of a compound of formula (I) at the 3- and 4-centres may conveniently be determined by routine and conventional X-ray crystallographic analysis of an isolated diastereomeric derivative of that isomer, the configuration at the 3- and 4- centres of the isomer and its derivative being the same. For example, an isomer of a compound of formula (I) wherein R5 is H may be reacted with a chiral esterifying agent with retention of 3- and 4- centre configuration to form a diastereomeric ester derivative of the isomer. This may be isolated as a crystalline solid and the crystals used for the foregoing X-ray analysis. An isomer of a compound of formula (I) wherein R5 is an alkyl or acyl group as hereinbefore defined may be converted conventionally to the corresponding isomer of a compound of formula (I) wherein R5 is H, with retention of 3- and 4- centre configuration. This may then be derivatised and its absolute configuratibn determined as described hereinbefore. The optical rotation of any similarly resolved and isolated enantiomer of the compound of formula (III) or any compound of formula (II) may be routinely ascertained by conventional methods. A process for the separation of diastereomeric derivatives of the isomers of a compound of formula (I), and for the resolution of the isomers of a compound of formula (I), is described hereinafter. One of R1 and R2 is hydrogen. The other is preferably selected from the class of alkylcarbonyl, alkoxycarbonyl, nitro or cyano, in particular nitro or cyano. The alkyl groups or alkyl moieties of alkylcontaining groups, in respect of the other of R1 and R2, are preferably methyl or ethyl. It is preferred that R2 is hydrogen and R1 is selected from the class of substituents as defined hereinbefore. It is particularly preferred that R2 is hydrogen and R1 is nitro or cyano. It is also preferred that R2 is hydrogen and Rl is acetyl. R3 and R4 are preferably both alkyl having from l to 4 carbon atoms. In particular they are each methyl or methyl, preferably each methyl. When R5 is alkyl, preferred examples thereof include methyl, ethyl and n- propyl, of which methyl is most preferred. When R5 is acyl, a preferred class is unsubstituted carboxylic acyl, such as aliphatic acyl or benzoyl. R5 however is preferably hydrogen. Preferably, the (3S,4R)-isomer of a compound of formula (I) is in a form containing from 0 to 40%, 0 to 30%, 0 to 20% or 0 to 10% of the corresponding (3R,4S)isomer. More preferably, the (3S,4R)-isomer is in a form containing 0 to 5% of the corresponding (3R,4S)-isomer. Most preferably, the (3S,4R)-isolner i; in a form containing 0% or no detectable amount of the corresponding (3R,4S)-isomer. All percentages hereinbefore are percentages of the mixture by weight. The presence of (3R,4S)-isomer may for example be routinely detected by the comparison of the optical rotation of a sample of the isomeric mixture with that of a pure sample of the (3S,4R)-isomer, or by the 1H nmr spectrum of a sample of the isomeric mixture in the presence of a chiral shift reagent or chiral solvatiny agent. The present invention also provides a process for the preparation of the (3S,4R)-isomer of a compound of formula (I), optionally in admixture with up to 45% of the mixture by weight of the corresponding (3R,4S)-isomer, which process comprises resolution of a mixture of (3S,4R)- and (4S,3R)-isomers of a compound of formula (I) to the extent that the resolution fraction which predominantly contains (3S,4R)-isomer optionally contains up to 45% of that resolution fraction by weight of the corresponding (3R,4S)-isomer; and optionally converting any R5 group in the (3S,4R)-isomer, and in the (3R,4S)-isomer when present, to another R5 group. The term 'resolution' is used herein in the conventional practical sense used in the art to ;Aclurle partial resolution, that is, the separation of a mixture of enantiomers of a compound (in any ratio) into two fractions, one of which is enriched in one enantiomer relative to the initial mixture. Resolution of the mixture of (3S,4R)- and (3R,4S)isomers of a compound of formula (I) may be effected conventionally by derivatising the mixture with a chiral derivatising agent, to form a mixture of diastereomers of a derivative of the compound of formula (I). The components of the mixture may then be separated conventionally, for example by fractional crystallisation. Separation may be complete, or partial, such that a given separated fraction comprises up to 45% of the total fraction by weight of the diastereomeric derivative of the (3R,4S)-isomer. Subsequently, the diastereorneric derivative of the desired (3S,4R)-isomer, optionally in admixture with the diastereomeric derivative of the (3R,4S)-isomer is converted to the desired (3S,4R)-isorner of the compound of formula (I), optionally in admixture with up to 45% of the (3R,4S)-isomer. The derivatisation for the process of the present invention is preferably effected on a mixture of (3S,4R)- and (3R,4S)-isomers of a compound of formula (I) wherein R5 is hydrogen, by reacting such a mixture of isomers with an optically active reagent suitable for resolving alcohols. Such reagents include optically active acids or acid derivatives, such as acid chlorides, acid anhydrides or isocyanates. One preferred reagent is (-)- -methylbenzyl isocyanate. The resolution process is carried out in accordance with conventional procedures. With the preferred reagent, (-)-a-methylbenzyl isocyanate, formation of the derivatives is preferably carried out by heating the isocyanate with the mixture of isomers at reflux temperature in an inert solvent such as toluene. The resulting residue, which is a mixture of carbamates, may then separate conventionally, for example by fractional crystallisation using a suitable solvent or solvent mixture, such as ethyl acetate and pentane. In this way the diastereomeric derivative of the (3S,4R)-isomer may be obtained as a crystalline material, optionally in admixture with the diastereomeric derivative of the (3K,4S)-isomer, depending on the process conditions, and the remainder of the diastereomeric derivative of the (3R,4S)-isomer remains in the mother liquor. It is preferred that process conditions are chosen such that, if present, the diastereomeric derivative of the (3R,4S)-isomer is only 45% or less of the total crystalline fraction, so that the fraction may be converted to give the desired (3S,4R)-isomer of the compound of formula (I) in the desired form as hereinbefore defined without the need for further fractional crystallisation. It will be appreciated that the optically active reagent could be such that the derivative of the (3R,4S)-isomer of a compound of formula (I) wherein R5 is hydrogen is initiallly isolated as crystalline material and the derivative of the desired (3S,4R)-isomer remains in the mother liquor, optionally with the derivative of the (3R,4S)-isomer also in the mother liquor. The derivative of the (3S,4R)-isomer optionally in admixture with the derivative of the (3R,4S)-isomer may be isolated from the mother liquor by conventional means such as further crystallisation. It is preferred that process conditions are chosen such that, if present, the derivative of the (3R,4S)-isomer is only present as 45% or less by weight of the total derivative of the compound of formula (I) present in the mother liquor, so that the crystals subsequently isolated from the mother liquor may be converted to give the desired (3S,4R)-isomer of the compound of formula (I) in the desired form as hereinbefore defined without the need for further fractional crystalli sation. It is preferred that separation of any diastereomeric derivatives is as complete as possible, so that the desired end-product (3S,4R)-isomer of a compound of formula (I) is in a form containing as little as possible of the (3R,4S)-isomer. Conversion of the (partially) separated diastereomeric derivative of the desired (3S,4R)-isomer of the compound of formula (I) to the (3S,4R)-isomer of the compound of formula (I) in the desired form as hereinbefore defined may be effected conventionally. For example, when the diastereomeric derivatives are esters, these may be hydrolysed conventionally, for example by warming them with trichlorosilane in the presence of a base, such as triethylamine, in an inert solvent such as toluene. It will be appreciated that the material for the foreoing resolution using diastereomeric ester derivatives is a mixture of (3S,4R)- and (3R,4S)-isomers of a compound of formula (I) wherein R5 is hydrogen. When it is desired to resolve a mixture of isomers of a compound of formula (I) wherein R5 is other than hydrogen, that is, alkyl or acyl as defined hereinbefore, it is generally necessary, in this preferred process, first to convert Rs to hydrogen by conventional de-etherification or de-esterification processes respectively; for example de-esterification may be effected as described hereinbefore for the diastereomeric ester derivatives of the compound of formula (I) (These methods are also applicable to all such R5 interconvertions hereinafter). Thus it will be appreciated that the starting material leading to the (3S,4R)isomer of a compound of formula (I) in the form hereinbefore defined is not necessarily the same compound of formula (I); it may differ in the R5 group. Generally however, it is convenient to use as a starting material the same compound of formula (I) as is desired in (partially) resolved form as the end-product. The mixture of (3S,4R)- and (3R,4S)-isomers used in the resolution process of the present invention normally contains at least about 50% of (3R,4S)-isomer. In fact, mixtures containing about 50% of each isomer are usually obtained from any one of the processes described hereinafter for the preparation of a compound of formula (I). When (partial) resolution of the isomers of a compound of formula (I) is effected using diastereomeric ester derivatives of a compound of formula (I) wherein R5 is hydrogen, it may be desired to convert the Rs hydrogen atom to other R5 as hereinbefore defined. The R5 hydrogen atom in the resolution product may be converted to alkyl or acyl as hereinbefore defined by conventional methods. (These methods are also applicable to all such R5 interconversions hereinafter). Preferably, the alkylating agent is an alkyl iodide, the reaction being carried out in an inert solvent, such as toluene in the presence of a base, such as potassium t-butoxide. Preferably, the acylating agent is a carboxylic acid or derivative thereof, the reaction being carried out in a non-hydroxylic soluent in the presence of a condensation promoting agent, such as dicyclohexylcarbodiimide. In the preferred case when R5 is hydrogen, there is of course no need to carry out any subsequent alkylation or acylation reaction. The (3R,4S)-isomer corresponding to the desired end-product (3S,4R)-isomer of the compound of formula (I) may be incorporated into a mixture with the (3S,4R)-isomer to the extent that it forms up to 45% of the mixture by weight. The (3R,4S)-isomer may be incorporated into the mixture at any stage in the process of the invention subsequent to (partial) resolution step. Thus the (3R,4S)-isomer corresponding to the desired (3S,4K)-isomer of the end-product compound of formula (I) may be added to that (3S,4K)-isomer (optionally already in admixture with (3R,4S)-isomer as hereinbefore defined)1 to the extent hereinbefore defined. Alternatively, the (3R,4S)-isomer of an intermediate compound of formula (I) (for example one where R5 is hydrogen) may be added to the corresponding (partially) resolved (3S,4R)-isomer, to the extent that it forms up to 45% of the mixture by weight. All R5 groups in the mixture may be converted to other R5 to incorporate the (3R,4S)-isomer corresponding to the desired end-product (3S,4R)-isomer of a compound of formula (I) into a mixture with that (3R,4S)-isomer as hereinbefore defined. It is preferred that there is no such subsequent incorporation of any such (3R,4S)-isomer corresponding to the desired (3S,4R)-isomer into a mixture therewith, so that the desired (3S,4R)-isomer of a compound of formula (I) is in a form containing as little as possible of the (3R,4S)-isomer. A mixture of isomers, usually in an approroximate 50;50 ra to, d E' a compound of formula ( I ) , Illly t) obtained by carrying out any one of the following processes 1 to 4. In all these processes it is preferred that, in any compound of formula (I) so prepared, R5 is hydrogen, so that the reaction product may be used directly in the preferred resolution process of the present invention using diastereomeric ester derivatives of a compound of formula (I) wherein R5 is hydrogen, without the need to convert R5 to hydrogen beforehand. Process 1. Cyclising a compound of formula (IV), or a metal salt thereof: EMI12.1 wherein one of R1 and R2 is hydrogen or a group or atom convertible into hydrogen and the other is one of the class of substituents as defined hereinbefore for the other of Rl and R2 or a group or atom convertible thereto, R3 to R5 and n are as defined hereinhefore, L] is a leaving group; and wherein the substituted amino group is trans to the OH group; in the case when one of R1 and R2 is a group or atom convertible into hydrogen, converting the group or atom into hydrogen; in the case when the other of Rl- and R2 is a group or atom convertible into one of the class of substituents as defined hereinbefore for the other of R1 and R2, converting the group or atom into one of the class of substituents as defined; and optionally converting R5 to other R5 as hereinbefore defined. The leaving group L1 is a group that is displaceable by a secondary amino nucleophile. Preferred examples of such groups include hydroxy and, in particular, Cl-4 alkoxy, such as ethoxy. The cyclisation is normally carried out by heating the compound of formula (IV) under reflux in an inert solvent, such as xylene or toluene. When a metal salt of formula (IV) is used, the sodium salt is preferred. However, it is even more preferred not to use a metal salt at all, especially as any elimination side reactions are thereby avoided. In the case where one of Rl or R2- is a group or atom convertible to the class of substituents, other than hydrogen, as defined hereinbefore for Ri or R2, such conversions are yenerally well-known in the art. In the case where Rl- or R2- is a group or atom convertible to hydrogen, such conversions are also generally well-known in the art. For example, a hydrogen atom may be replaced by a nitro group by nitrating in a known manner a compound of formula (IV), wherein one of R1 and R2- is hydrogen. An acetamido group may be replaced by a hydrogen atom by hydrolysing a compound of formula (IV) wherein one of Rl'and R2-is acetamido, converting the resulting amine into a diazonium salt, and finally decomposing it in reductive conditions. It is however preferred that any conversions are carried out at an earlier stage as mentioned hereinafter. Compounds of formula (IV) can be prepared by reacting a compound of formula (V); EMI14.1 wherein Rl- and R2 and R3 and K4 are as defined hereinbefore, with a compound of formula (VI); or a salt thereof: H2N-(CH2)n+2-COL1 (VI) wherein n and L1 are as defined hereinbefore; and optionally converting the Rs hydrogen atom in the resulting compound of formula (IV) to other Rs as hereinbefore defined. The reaction is normally carried out in a solvent at low, medium or high temperature. The solvent may be an alcohol, such as methanol or ethanol. When L1 is hydroxy the reaction proceeds well if carried out in refluxing ethanol in the presence of aqueous sodium carbonate. When L1 is C14 alkoxy, the compound of formula (VI) is preferably used in the form of a salt and the reaction is preferably carried out in the presence of sodium hydroxide in ethanol. Under sorne conditions, the compound of formula (I) spontaneously cyclises to form a compound of formula (I). Compounds of formula (V) can be prepared, preferably in situ, by reacting a compound of formula (VII): EMI15.1 wherein Rl- and R2- and R3 and R4 are as defined hereinbefore and the hydroxy group is trans to the bromo atom, with a base, such as potassium hydroxide, in ether or aqueous dioxan. Alternatively, compounds of formula (IV) can be prepared by reacting a compound of formula (VIII): EMI15.2 wherein R1-, R2-, R3 and R4 are as defined hereinbefore, and the amino group is trans to the hydroxy group, with a compound of formula (IX): L2(CH2)n+2cOLl (IX) wherein n and L1 are as defined hereinbefore and L2 is a leaving group; and optionally converting the K5 hydrogen atom in the resultant compound to other R5 as hereinbefore defined. The leaving group, L2, is a group that is displaceable by a primary amino nucleophile. Preferred examples of such groups include halo, such as chloro and bromo. Compounds of formula (VIII) can be prepared by a reaction of a compound of formula (V) with ethanolic ammonium hydroxide solution. Alternatively, they can be prepared by reduction with zinc and hydrochloric acid of a compound of formula (X): EMI16.1 wherein Rl-, R2c, R3 and R4 are as defined hereinbefore and wherein the azide group is trans to the hydroxy group. Compounds of formula (X) can in turn be prepared from a compound of formula (V) by reaction with sodium azide in the presence of boric acid in for example dimethylformamide. Process 2. Oxidising a compound of formula (XI), or a metal salt thereof: EMI17.1 wherein R1-, R2 , R3, to R5 and n are as defined hereinbefore, and wherein the cyclic aminol group is trans to the ORg group; in the case when one of R1 and K2 is a group or atom convertible into hydrogen, converting the group or atom into hydrogen; in the case when the other of R1 and R2- is a group or atom convertible into one of the class of substituents as defined hereinbefore for the other of R1 and R2, converting the group or atom into one of the class of substituents as defined, and optionally converting K5 into other R5 as hereinbefore defined. The oxidation is preferably carried out in a solvent such as aqueous methanol with a metal periodate such as potassium periodate. Compounds of formula (XI) can be prepared by cyclising in the presence of an acid a compound of formula (XII): EMI18.1 wherein R1, R2 , R3 to Rs and n are as defined hereinbefore and wherein the substituted amino group is trans to the ORg group. Compounds of formula (XII) can in turn be prepared by reacting a compound of formula (V) with a compound of formula (XIII): H2N(CH2)n+2CH(OCH3)2 (XIII) wherein n is as defined hereinbefore. Process 3. Reacting a compound of formula (V) with an anion of formula (XIV): EMI18.2 wherein n is as defined hereinbefore; in the case when one of R1- and R2 is a group or atom convertible into hydrogen, converting the group or atom into hydrogen; and, in the case when the other of Rl- and R2- is a group or atom convertible into one of the class of substituents as defined hereinbefore for the other of R1 and R2, converting the group or atom into one of the class of substituents as defined; and optionally converting R5 hydrogen in the resultant compound into other Rs as hereinbefore defined. The reaction is preferably carried out in a solvent such as dimethylsulphoxide in the presence of a base, such as sodium hydride. The compound of formula (V) can be prepared in situ from the corresponding compound of formula (VII). In such circumstances, it is advantageous not to add the lactam anion of formula (XIV) until sufficient time has elapsed for the epoxide of formula (V) to be produced. 4) Cyclising a compound of formula (tV): EMI19.1 wherein R1-, R2, R3 to R5 and n are as defined hereinbefore and L3 is a leaving group, and wherein the substituted amino group is trans to the OR5 group; in the case when one of R1- and R2- is a group or atom convertible into hydrogen, converting the group or aton into hydrogen; and, in the case when the other of R1 and R2 is a group or atom convertible into one of thf. lass of substituents as defined hereinhefore for t other of R1 and R2, converting the group or atom into one of the class of substituents as defined; and optionally converting Rs to other R5 as hereinbefore defined. The leaving group L3 is a group that is displaceable by a secondary amino nucleophile adjacent a carbonyl function. A preferred example is chloro. The cyclisation reaction is preferably carried out in a solvent such as dimethylformamide in the presence of a base, such as sodium hydride. Compounds of formula (XV) can be prepared by reacting a compound of formula (VIII) with a compound of formula (XVI): L3(CH2)n+2COL4 (XVI) wherein L3 and n are as defined hereinbefore and L4 is a leaving group, and optionally converting Rs hydrogen in the resultant compound to other Rg. The leaving group L4 is a group that, when adjacent to a carbonyl function, is displaceable by a primary amino nucleophile. The reaction is preferably carried out in a solvent, such as chloroform or methylene chloride, in the presence of aqueous base, such as aqueous sodium hydroxide. In the reactions with the epoxide of formula (V), the trans isomer is specifically formed. Compounds of formula (VII) can be prepared in accordance with known processes. Schematically, such prowess can be depicted thus: EMI21.1 ta) Room temperature; NaOH/40% benzyltrimethyl ammonium hydroxide in methanol; (b) Heat in o-dichlorobenzene; (c) N-bromosuccinimide/dimethylsulphoxide/water; (d) Bromine in carbon tetrachloride; and (e) Acetone/water. The above process can produce mixtures of compounds during reaction (b) owing to the two sites available for ring formation. It is therefore advisable to remove any of the undesired compound by, for example, chromatography, before reaction (c) or (d). Instead of carrying out the conversion of a group or atom Rl' or R2' into hydrogen or into one of the class of substituents defined for the other of R1 and R2 after cyclising a compound of formula (IV) or (XV), or after oxidising a compound of formula (XI), or after reacting a compound of formula (V) with an anion of formula (XIV), it is greatly preferred that any such conversions are carried out at an earlier stage, preferably on the chromene produced after reaction (b) above. In other words, it is preferred that, for the processes of the invention Rl- and R2- are R1 and R2 respectively. The (3S,4R)-isomer of a compound of formula (I) has a better blood pressure lowering activity than the corresponding (3R,4S)-isomer. This isomer is therefore useful in the treatment of hypertension, optionally in admixture with the corresponding (3R,4S)-isomer as hereinbefore defined. The present invention accordingly provides a pharmaceutical composition which comprises the (3S,4R)-isomer of a compound of formula (I) optionally in admixture with up to 45% of the mixture of isomers by weight of the corresponding (3R,4S)-isomer and a pharmaceutically acceptable carrier. In particular, the present invention provides an antihypertensive pharmaceutical composition which comprises an anti-hypertensive effective amount of the (3S,4R)-isomer of a compound of formula (I) optionally in admixture with up to 45% of the mixture of isomers by weight of the corresponding (3R,4S)-isomer and a pharmaceutically acceptable carrier. The compositions are preferably adapted for oral administration. However, they may be adapted for other modes of administration, for example parenteral administration for patients suffering from heart failure. The compositions may be in the form of tablets, capsules, powders, yranules, lozenges, suppositories, reconstitutable powders, or liquid preparations, such as oral or sterile parenteral solutions or suspensions. In order to obtain consistency of administration it is preferred that a composition of the invention is in the form of a unit dose. Unit dose presentation forms for oral administration may be tablets and capsules and may contain conventional excipients such as binding agents, for example syrup, acacia, gelatin, sorbitol, tragacanth, or polyvinylpyrrolidone; fillers, for example lactose, sugar, maize-starch, calcium phosphate, sorbitol or glycine; tabletting lubricants, for example magnesium stearate; disintegrants, for example starch, polyvinylpyrrolidone, sodium starch glycollate or microcrystalline cellulose; or pharmaceutically acceptable wetting agents such as sodium lauryl sulphate. The solid oral compositions may be prepared by conventional methods of blending, filling, tabletting or the like. Repeated blending operations may be used to distribute the active agent throughout those compositions employing large quantities of fillers. Such operations are of course conventional in the art. The tablets may be coated according to methods well known in normal pharmaceutical practice, in particular with an enteric coating. Oral liquid preparations may be in the form of, for example, emulsions, syrups, or elixirs, or may be presented as a dry product for reconstitution with water or other suitable vehicle before use. Such liquid preparations may contain conventional additives such as suspending agents, for example sorbitol, syrup, methyl cellulose, gelatin, hydroxyethylcellulose, carboxymethylcellulose, aluminium stearate gel,hydroyenated edible fats; emulsifying agents, for example lecithin, sorbitan monooleate, or acacia; non-aqueous vehicles (which may include edible oils), for example almond oil, fractionated coconut oil, oily esters such as esters of glycerine, propylene glycol, or ethyl alcohol; preservatives, for example methyl or propyl p-hydroxybenzoate or sorbic acid; and if desired conventional flavouring or colouring agents. For parenteral administration, fluid unit dosaye forms are prepared utilizing the compound and a sterile vehicle, and, depending on the concentration used, can be either suspended or dissolved in the vehicle. In preparing solutions the compound can be dissolved in water for injection and filter sterilized before filling into a suit, able vial or ampoule and sealiny. Advantageously, adjuvants such as a local anaesthetic, a preservative and buffering agents can be dissolved in the vehicle. To enhance the stability, the composition can be frozen after filling into the vial and the water removed under vacuum. Parenteral suspensions are prepared in substantially the same manner, except that the compound is suspended in the vehicle instead of being dissolved, and sterilization cannot be accomplished by filtration. The compound can be sterilized by exposure to ethylene oxide before suspending in the sterile vehicle. Advantageously, a sufactant or wetting agent is included in the composition to facilitate uniform distribution of the compound. The compositions may contain from 0.1% to 99% by weight, preferably from 10-60% by weight, of the active material, depending on the method of administration. The present invention further provides a method of prophylaxis or treatment of hypertension in mammals including man, which comprises administering to the suffering mammal an anti-hypertensive effective amount of the (3S,4R)-isomer of a compound of formula (I) optionally in admixture with up to 45% of the mixture of isomers by weight of the corresponding (3R,4S)-isomer, or a pharmaceutical composition of the invention. An effective amount will depend on the relative efficacy of the compounds of the present invention, the severity of the hypertension being treated and the weight of the sufferer. However, a unit dose form of a composition of the invention may contain from 0.5 to 100 mg of a compound of the invention and more usually from 1 to 50 mg, for example 1 to 10 mg, such as 1, 2, 5, or 10mg. Such compositions may be administered from 1 to 6 times a day, more usually from 1 to 4 times a day, in a manner such that the daily dose is from 1 to 100mgfor a 70 kg human adult and more particularly from 1 to 10 mg. The present invention further provides the (3S,4R)-isomer of a compound of formula (I) optionally in admixture with up to 45% of the mixture of isomers by weight of the corresponding (3R,4S)-isomer for use in the treatment or prophylaxis of hypertension. The following example illustrates the resolution of the (3S,4R)-isomer of a compound of formula (I). Example Resolution of 6-cyano-3,4-dihydro-2,2-dimethyl-trans4-(2-oxo-1-pyrrolidinyl)-2H-benzo[b)pyran-3-ol (1) A mixture of the title compound (16.6mM) and (-)-a-methylbenzyl isocyanate (19.3mM) in toluene (160 ml) was refluxed for 43 h and then evaporated to leave a gum. Fractional crystallisation from ethyl acetate-pentane afforded the carbamate of the (-) isomer of the title compound, [a]26(acetone)-l4.2401 in 21% yield. Crystallisation of the oil derived from the mother liquor similarly gave the carbamate of the (+) isomer of the title compound [a]D26 (acetone)-77.12 , in 14% yield. The foregoing carbamates were each hydrolysed back to the parent carbinols by treatment with triethylamine (two equivalents) and trichlorosilane (two equivalents) in toluene at 35-41)0C for 16 h. The crude products were purified by chromatography on silica gel, eluting with ethyl acetate, to afford the pure (-) isomer of the title compound, L]D26 (CHCl3)-52.2 , m.p. 242-4oC (63%)', and (+)-isomer of the title compound [a]D26 (CHC13) +53.5 , m.p. 243-5 C (66%) respectively. The following compounds are resolved analogously: 6-acetyl-3, 4-dihydro-2, 2-dimethyl-trans-4- (2-oxo-1-piperidinyl)-2H-benzo[b]pyran-3-ol(2) 6-acetyl-3,4-dihydro-2,2-dimethyl-trans-4-(2-oxo-l- pyrrolidinyl)-2H-benzo[b]pyran-3-ol (3) 6-cyano-3,4-dihydro-2,2-dimethyl-trans-4-(2-oxo-l- piperidinyl)-2H-benzo[b]pyran-3-ol (4) 6-nitro-3,4-dihydro-2,2-dimethyl-trans-4-(2-oxo-l- pyrrolidinyl)-2H-benzo[b]pyran-3-o1 (5) 6-nitro-3, 4-dihydro-2, 2-dimethyl-trans-4-(2-oxo-1- piperidinyl)-2H-benzo[b]pyran-3-ol (6) Pharmacological Data Systolic blood pressures were recorded by a modification of the tail cuff method described by I.M. Claxton, M.G. Palfreyman, R.H. Poyser, R.L. Whiting, European Journal of Pharmacology, 37, 179 (1976). W+W BP recorder, model 8005, was used to display pulses. Prior to all measurments rats were placed in a heated environment (33.5t0.50C) before transfer to a restraining cage. Each determination of blood pressure was the mean of at least 6 readings. Spontaneously hypertensive rats (ages 12-18 weeks) with systolic blood pressures > 170 mmHg were considered hypertensive. Compound (I) Time Post %Change in %Change of Example Dose Hours Systolic Blood in (3S,4R)-isomer Blood Heart Rate 5 rats Dose 0.3 mg/kg 1 -59 # 4 -2 + 2 p.o. 2* -52 # 7 -6 # 3 Initial Blood pressure 4** -32 -15 180i7mmHg 6* -28 1 8 -5 1 1 Initial Heart Rate 24*** -14 + 7 -3 i 2 507+5beats/min * 2 rats had no measurable pulse ** 3 rats had no measurable pulse *** 4 rats only, were used to determine heart rate, and blood pressure. Toxicity No toxic effects were observed in the above tests.

Claims: Claims 1. The (3S,4R)-isomer of a compound of formula (I) optionally in admixture with up to 45% of the mixture by weight of the corresponding (3R,4S)-isomer; EMI29.1 wherein: one of R1 and R2 is hydrogen and the other is selected from the class of alkylcarbonyl, alkoxycarbonyl, alkylcarbonyloxy, alkylhydroxymethyl, nitro, cyano, chloro, trifluoromethyl, alkylsulphinyl, alkylsulphonyl, alkoxysulphinyl, alkoxysulphonyl, alkylcarbonylamino, alkoxycarbonylamino or aminosulphinyl, aminosulphonyl or aminocarbonyl, the amino moiety being optionally substituted by one or two alkyl groups, or alkylsulphinylamino, alkylsulphonylamino, alkoxysulphinylamino or alkoxysulphonylamino or ethylenyl terminally substituted by alkylcarbonyl, nitro or cyano, or -C(alkyl)NOH or -C(alkyl)NNH2, the alkyl groups or alkyl moieties of alkyl-containing groups having from 1 to 6 carbon atoms; one of R3 and R4 is hydrogen or alkyl having from 1 to 4 carbon atoms and the other is alkyl having from 1 to 4 carbon atoms, or R3 and R4 together are C2-S polymethylene; R5 is hydrogen, alkyl having from 1 to 3 carbon atoms or acyl having from 1 to 8 carbon atoms; and n is 1 or 2 2. A (3S,4R)-isomer of a compound of formula (I), according to claim 1, in the form defined in claim 1, which isomer has a negative optical rotation. 3. A (3S,4R)-isomer of a compound of formula (I), according to claim 1 or 2, in the form defined in claim 1, which isomer is the (3S,4R)-isomer of: 6-cyano-3,4-dihydro-2,2-dimethyl-trans-4-(2-oXo-1- pyrrolidinyl)-2H-benzo[b]pyran-3-ol, 6-acetyl-3, 4-dihydro-2, 2-dimethyl-trans-4- (2-oxo-1-piperidinyl)-2H-benzotb]pyran-3-ol, 6-cyano-3,4-dihydro-2,2-dimethyl-trans-4 (2-oxo-l-piperidinyl)-2H-benzo[b]pyran-3-ol, 6-acetyl-3, 4-dihydro-2, 2-dimethyl-trans-4- (2-oxo-l-pyrrolidinyl ) -2H-benzo [b] pyran-3-ol, 6-nitro-3, 4-dihydro-2, 2-dimethyl-trans-4- (2-oxo-1-pyrrolidinyl ) -2H-benzo [b] pyran-3-ol, or 6-nitro-3, 4-dihydro-2, 2-dimethyl-trans-4- (2-oxo-l-piperidinyl)-2H-benzo [b]pyran-3-ol, 4. A (3S,4R)-isomer of a compound of formula (I), according to any of the claims 1 to 3, in the form defined in claim 1, which is the (3S,4R)-isomer of 6-cyano-3,4-dihydro-2,2-dimethyl-trans-4-(2-oxo-1- pyrrolidinyl)-2H-benzo[b]pyran-3-ol. 5. A (3S,4R)-isomer of a compound of formula (I), according to any one of claims 1 to 4, in the form defined in claim 1, wherein the (3S,4R)-isomer is in admixture with 0% or no detectable amount of the corresponding (3R,4S)-isomer. 6. A process for the preparation of the (3S,4R)-isomer of a compound of formula (I) according to claim 1, optionally in admixture with up to 45% of the mixture by weight of the corresponding (3R,4S)-isomer, which process comprises resolution of a mixture of (3S,4R)- and (4S,3R)-isomers of a compound of formula (I) as in claim 1 to the extent that the resolution fraction which predominantly contains (3S,4R)-isomer optionally contains up to 45% of that resolution fraction by weight of the corresponding (3R,4S)-isomer; and optionally converting any K5 group as defined in claim 1 in the (3S,4R)-isomer, and in the (3R,4S)-isomer when present, to another Rs group. 7. A process according to claim 6, wherein the mixture of (3S,4R)- and (3R,4S)-isomers of a compound of formula (I) is completely resolved, to give a (3S,4R)-isomer of a compound of formula (I), according to claim 1, in the form defined in claim 5. 8. A pharmaceutical composition which comprises the (3S,4R)-isomer of a compound of formula (I), according to claim 1, optionally in admixture with up to 45% of the mixture of isomers by weight of the corresponding (3R,4S)-isomer and a pharmaceutically acceptable carrier. 9. A composition according to claim 8 wherein the (3S,4R)-isomer is in admixture with 0% or no detectable amount of the corresponding (3R,4S)-isomer. 10. A composition according to claim 8 or 9 wherein the compound of formula (I) according to claim 1 is 6-cyano-3f4-dihydro-22-dimethyl-trans-4-(2 pyrrolidinyl)-2H-benzolb3pyran-3-ol. 11. The (3S,4R)-isomer of a compound of formula (I), according to claim 1, optionally in admixture with up to 45% of the mixture by weight of the corresponding (3R,4S)-isomer for use in the treatment or prophylaxis of hypertension. 12. An isomer of a compound of formula (I) EMI32.1 wherein: one of R1 and R2 is hydrogen and the other is selected from the class of alkylcarbonyl, alkoxycarbonyl, alkylcarbonyloxy, alkylhydroxymethyl, nitro, cyano, chloro, trifluoromethyl, alkylsulphinyl, alkylsulphonyl, alkoxysulphinyl, alkoxysulphonyl, alkylcarbonylamino, alkoxycarbonylamino or aminosulphinyl, aminosulphonyl or aminocarbonyl, the amino moiety being optionally substituted by one or two alkyl groups, or alkylsulphinylamino, alkylsulphonylamino, alkoxysulphinylamino or alkoxysulphonylamino or ethylenyl terminally substituted by alkylcarbonyl, nitro or cyano, or -C(alkyl)NOH or -C(alkyl)NNH2, the alkyl groups or alkyl moieties of alkyl-containing groups having from 1 to 6 carbon atoms; ; one of R3 and R4 is hydrogen or alkyl having from 1 to 4 carbon atoms and the other is alkyl having from 1 to 4 carbon atoms, or R3 and R4 together are C2-5 polymethylene; R5 is hydrogen, alkyl having from 1 to 3 carbon atoms or acyl having from 1 to 8 carbon atoms; and n is 1 or 2; which isomer has the same configuration as that enantiomer of a compound of formula (III) which has a negative optical rotation: EMI33.1 and which is optionally in admixture with up to 45% of the mixture by weight of the other isomer of the compound of formula (I). 13. An isomer of a compound of formula (I) according to claim 12, in the form defined in claim 12, which isomer has a negative optical rotation. 14. An isomer of a compound of formula (I), accordng to claim 12 or 13, in the form defined in claim 12, which isomer is that isomer of: 6-cyano-3,4-dihydro-2,2-dimethyl-trans-4-(2-oXo-l- pyrrolidinyl)-2H-benzo[b]pyran-3-ol, 6-acetyl-3, 4-dihydro-2, 2-dimethyl-trans-4- (2-oxo-1-piperidinyl)-2H-benzo [b]pyran-3-ol, 6-cyano-3,4-dihydro-2,2-dimethyl-trans-4 (2-oxo-1-piperidinyl)-2H-benzo[b]pyran-3-ol, 6-acetyl-3,4-dihydro-2, 2-dimethyl-trans-4- (2-oxo-l-pyrrolidinyl ) -2H-benzo [b] pyran-3-ol, 6-nitro-3, 4-dihydro-2, 2-dimethyl-trans-4- (2-oxo-l-pyrrolidinyl)-2H-benzo[b]pyran-3-olt or 6-nitro-3,4-dihydro-2, 2-dimethyl-trans-4- (2-oxo-1-piperidinyl)-2H-benzo[b3pyran-3-ol, which has the same configuration as the isomer of the compound which is defined in claim 12, EMI34.1 15. An isomer of a compound of formula (I), according to any one of claims 12 to 14, in the form defined in claim 12, which is that isomer of 6-cyano-3,4-dihydro2,2-dimethyl-trans-4-(2-oxo-1-pyrrolidinyl)-2H-benzo[b] pyran-3-ol having the same configuration as the isomer of the compound of formula (III) which is defined in claim 12. 16. An isomer of a compound of formula (I), according to any one of claims 12 to 15, in the form defined in claim -12, wherein the isomer of the compound of formula (I) having the same configuration as the isomer of the compound of formula (III) which is defined in claim 12 is in admixture with 08 or no detectable amount of the other isomer of the compound of formula (I). 17. A process for the preparation of an isomer of a compound of formula (I), according to claim 12, which isomer has the same configuration as the enantiomer of a compound of formula (III) defined in claim 12, and is in the form defined in claim 12, which process comprises resolution of a mixture of two isomers of a compound of formula (I) as in claim 12, the two isomers in the mixture respectively having the same configuration as the two enantiomers of a compound of formula (III) as in claim 12, resolution being effected to the extent that the resolution fraction which predominantly contains that isomer of the resolved compound of formula (I) which has the same configuration as the enantiomer of compound of formula (III) as defined in claim 12 optionally contains up to 45% of that resolution fraction by weight of the other isomer of the resolved compound of formula (I); and optionally converting any Rs group as defined in claim 1 in that isomer of the resolved compound of formula (I) which has the same configuration as the enantiomer of a compound of formula (III) as defined in claim 12, and in the other isomer of the resolved compound of formula (I) when present, to another K5 group. 18. A process according to claim 17, wherein the mixture of the isomers of a compound of formula (I) is completely resolved, to give that isomer of a compound of formula (I), according to claim 12, which has the same configuration as the enantiomer of the compound of formula (III) as defined in claim 12, in the form defined in claim 16. 19. A pharmaceutical composition which comprises that isomer of a compound of formula (I), according to claim 12, which has the same configuration as the enantiomer of the compound of formula (III) as defined in claim 12, optionally in admixture with up to 458 of the mixture of isomers by weight of the other isomer of the compound of formula (I), and a pharmaceutically acceptable carrier. 20. A composition according to claim 19 wherein that isomer of the compound of formula (I), according to claim 12, which has the same configuration as the enantiomer of the compound of formula (III) as defined in claim 12, is in admixture with 0% or no detectable amount of the other isomer of the compound of formula (I). 21. A composition according to claim 19 or 20 wherein the compound of formula (I) according to claim 12 is 6-cyano-3,4-dihydro-2,2-dimethyl-trans-4-(2-oXo-1- pyrrolidinyl)-2H-benzo[b]pyran-3-ol. 22. An isomer of a compound of formula (I), according to claim 12, which isomer has the same configuration as the enantiomer of the compound of formula (III) as defined in claim 12, optionally in admixture with up to 45% of the mixture by weight of the other isomer of the compound of formula (I), for use in the treatment or prophylaxis of hypertension. 23. The (3S,4R), (-)-isomer of a compound of formula (I) optionally in admixture with up to 45% of the mixture by weight of the corresponding (3R,4S), (+)-isomer: EMI36.1 wherein: one of R1 and R2 is hydrogen and the other is selected from the class of alkylcarbonyl, alkoxycarbonyl, alkylcarbonyloxy, alkylhydroxymethyl, nitro, cyano, chloro, trifluoromethyl, alkylsulphinyl, alkylsulphonyl, alkoxysulphinyl, alkoxysulphonyl, alkylcarbonylamino, alkoxycarbonylamino or aminosulphinyl, aminosulphonyl or aminocarbonyl, the amino moiety being optionally substituted by one or two alkyl groups, or alkylsulphinylamino, alkylsulphonylamino, alkoxysulphinylamino or alkoxysulphonylamino or ethylenyl terminally substituted by alkylcarbonyl, nitro or cyano, or -C(alkyl)NOH or -C(alkyl)NNH21 the alkyl groups or alkyl moieties of alkyl-containing groups having from 1 to 6 carbon atoms; one of R3 and R4 is hydrogen or alkyl having from 1 to 4 carbon atoms and the other is alkyl having from 1 to 4 carbon atoms, or R3 and R4 together are C25 polymethylene; K5 is hydrogen, alkyl having from 1 to 3 carbon atoms or acyl having from 1 to 8 carbon atoms; and n is 1 or 2. 24. A (-)-isomer of a compound of formula (I), according to claim 23, in the form defined in claim 1, which isomer is the (-)-isomer of: 6-cyano-3,4-dihydro-2,2-dimethyl-trans-4-(2-oXo-1- pyrrolidinyl)-2H-benzo [b] pyran-3-ol, 6-acetyl-3, 4-dihydro-2, 2-dimethyl-trans-4- (2-oxo-1-piperidinyl)-2H-benzo[b]pyran-3-ol, 6-cyano-3,4-dihydro-2,2-dimethyl-trans-4 (2-oxo-1-piperidinyl)-2H-benzo[b]pyran-3-ol, 6-acetyl-3, 4-dihydro-2, 2-dimethyl-trans-4- (2-oxo-1-pyrrolidinyl) -2H-benzo [bi pyran-3-ol, 6-nitro-3, 4-dihydro-2, 2-dimethyl-trans-4- (2-oxo-1-pyrrolidinyl)-2H-benzo[b]pyran-3-ol, or 6-nitro-3, 4-dihydro-2, 2-dimethyl-trans-4- (2-oxo-l-piperidinyl) -2H-benzo [b) pyran-3-ol, 25. A (-)-isomer of a compound of formula (I), according to claim 23 or 24, in the form defined in claim 23, which is the (-)-isomer of 6-cyano-3,4 dihydro-2,2-dimethyl-trans-4-(2-oxo-1-pyrrolidinyl) -2H-benzotbjpyran-3-ol. 26. A (-)-isomer of a compound of formula (I) according to any one of claims 23 to 25, in the form defined in claim 23, wherein the (-) isomer is in admixture with 0% or no detectable amount of the corresponding (+)-isomer. 27. A process for the preparation of the (-)-isomer of a compound of formula (I), according to claim 23, optionally in admixture with up to 45% of the mixture by weight of the corresponding (+)-isomer, which process comprises resolution of a mixture of (-)- and (+)- isomers of a compound of formula (I) as in claim 23 to the extent that the resolution fraction which predominantly contains (-)-i-somer optionally contains up to 45% of that resolution fraction by weight of the corresponding (+)-isomer; and optionally converting any R5 group as defined in claim 23 in the (-)-isomer, and in the (+)-isomer when present, to another Rs group. 28. A process according to claim 27, wherein the mixture of (-)- and (+)- isomers of a compound of formula (I) is completely resolved, to give a (-)-isomer of a compound of formula (I), according to claim 23, in the form defined in claim 26. 29. A pharmaceutical composition which comprises the (-)-isomer of a compound of formula (I), according to claim 23, optionally in admixture with up to 45% of the mixture of isomers by weight of the corresponding (+)-isomer and a pharmaceutically acceptable carrier. 30. A composition according to claim 29 wherein the (-)-isomer is in admixture with 0% or no detectable amount of the corresponding (+)-isomer. 31. A composition according to claim 29 or 30 wherein the compound of formula (I) according to claim 23 is 6-cyano-3,4-dihydro-2,2-dimethyl-trans-4-(2-oXo-1- pyrrolidinyl)-2H-benzo[b]pyran-3-ol. 32. The (-)-isomer of a compound of formula (I), according to claim 23, optionally in admixture with up to 45% of the mixture by weight of the corrsponding (+)-isomer for use in the treatment or prophylaxis of hypertension.

Inventors: FARUK, EROL
Applicants: BEECHAM GROUP PLC
Application year: 1984
Main classification: C07D405
IPC codes: C07D311, A61P9, A61K31, C07D405, C07D211, C07D207